ADAM CHERRY: Open Payments
NPI 1770805673 · LONGVIEW, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,518 in 95 payments from 18 companies in 2025. Trend: 2023 $1,189 · 2024 $5,458 · 2025 $3,518
Food & beverage: $2,078Consulting: $1,440
| Company | Payments | Amount |
|---|---|---|
| BioCryst Pharmaceuticals, Inc. | 1 | $1,428 |
| AstraZeneca Pharmaceuticals LP | 21 | $503 |
| CSL Behring | 17 | $271 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $258 |
| Novartis Pharmaceuticals Corporation | 9 | $240 |
| GlaxoSmithKline, LLC. | 9 | $194 |
| Amgen Inc. | 7 | $177 |
| Pharming Healthcare, Inc. | 4 | $92 |
| Regeneron Healthcare Solutions, Inc. | 3 | $76 |
| BioCryst US Sales Co., LLC | 2 | $50 |
Products named: ORLADEYO, TEZSPIRE, Hizentra, CUVITRU, AIRSUPRA, Rhapsido, NUCALA, RUCONEST.
Industry payments across WA — which companies pay providers there.
